Luminex Corporation Third Quarter Earnings Release Scheduled for October 26, 2005

AUSTIN, Texas, Oct. 10  /PRNewswire-FirstCall/ -- Luminex Corporation (NASDAQ:LMNX) announced today that it expects to report third quarter 2005 results on Wednesday, October 26, 2005.  Results are scheduled for release after the close of trading on the Nasdaq Stock Market.

Management will hold a conference call to discuss the operating highlights and financial results for the third quarter on Wednesday, October 26, 2005 at 5:00 p.m. Eastern time.

The conference call will be webcast live by CCBN and will be accompanied by a slide presentation, both of which can be accessed at Luminex Corporation's website at http://www.luminexcorp.com/ .  Simply log on to the web at the address above, go to the Company section and access the Investor Relations link.  Please go to the website at least fifteen minutes prior to the call to register, download and install any necessary audio/video software. If you are unable to participate during the live webcast, the call and slides will be archived for one year on the website http://www.luminexcorp.com/ .  To access the replay, click on the 'replay' link.

The use of pop-up blocking software may impair your ability to view webcasts.  If you use this software, press and hold the CTRL key when you click on the Register button.  Please contact your IT group if you are unable to override this feature.  Unauthorized recording or downloading of this event is not permitted.

Luminex Corporation develops, manufactures and markets proprietary biological testing technologies with applications throughout the life sciences industry.  The Company's xMAP(R) system is an open-architecture, multi-analyte technology platform that delivers fast, accurate and cost-effective bioassay results to markets as diverse as pharmaceutical drug discovery, clinical diagnostics and biomedical research, including the genomics and proteomics research markets.  The Company's xMAP technology is sold worldwide and is in use in leading research laboratories as well as major pharmaceutical, diagnostic and biotechnology companies.  Further information on Luminex Corporation or xMAP can be obtained on the Internet at http://www.luminexcorp.com/ .

Statements made in this release that express Luminex's or management's intentions, plans, beliefs, expectations or predictions of future events are forward-looking statements.  The words "believe," "expect," "intend," "estimate," "anticipate," "will," "could," "should" and similar expressions are intended to further identify such forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995.  It is important to note that the Company's actual results or performance could differ materially from those anticipated or projected in such forward-looking statements. Factors that could cause Luminex's actual results or performance to differ materially include risks and uncertainties relating to, among others, market demand and acceptance of Luminex's products, the Company's dependence on strategic partners for development, commercialization and distribution of products, fluctuations in quarterly results due to a lengthy and unpredictable sales cycle, Luminex's ability to scale manufacturing operations, potential shortages of components, competition, the timing of regulatory approvals and any modification of the Company's operating plan in response to its ongoing evaluation of its business, as well as the risks discussed under the heading "Risk Factors" in Luminex's Annual Report on Form 10-K for the year ended December 31, 2004, as filed with the Securities and Exchange Commission.  The forward-looking statements contained herein represent the judgment of Luminex as of the date of this press release, and Luminex expressly disclaims any intent, obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in Luminex's expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based.

   Contact:  Harriss T. Currie
             Vice President, Finance
             Chief Financial Officer
             512.219.8020
             

DATASOURCE: Luminex Corporation



CONTACT:  Harriss T. Currie, Vice President, Finance, Chief Financial

Officer of Luminex Corporation, [phone], or  



Web site:  http://www.luminexcorp.com/ 

Copyright